In people with atrial fibrillation (AF), periods of sinus rhythm present an opportunity to detect prothrombotic atrial remodeling through measurement of P-wave indices (PWIs)-prolonged P-wave duration, abnormal P-wave axis, advanced interatrial block, and abnormal P-wave terminal force in lead V1. We hypothesized that the addition of PWIs to the CHA 2 DS 2 -VASc score would improve its ability to predict AFrelated ischemic stroke.
Study Population
The ARIC study was designed to evaluate risk factors, etiology, and clinical manifestations of atherosclerotic coronary heart disease in the general population. Between 1987 and 1989, 15 792 men and women 45 to 64 years of age were recruited and enrolled from 4 US communities (Washington County, MD; Forsyth County, NC; Jackson, MS; and suburban Minneapolis, MN). After the baseline examination, participants completed 5 follow-up study visits, the most recent in 2016-2017. In between study visits, participants (or proxy) have been contacted annually by telephone (semiannually since 2012) to ascertain information on hospitalizations and deaths. Active communitywide surveillance of local hospitals has been performed to identify additional hospitalizations and cardiovascular events. Further details regarding outcome ascertainment procedures, study design, and population statistics have been previously described. 22 Approval for the study was obtained from the institutional review board on human research at each participating institution, and all participants provided informed consent.
The present analysis utilized data obtained from the baseline study visit in 1987-1989 through 2013. We excluded participants with missing ECG data (n=242), missing P-wave indices at baseline (n=45), prevalent AF (n=37), and those who were not white or black from all study sites and nonwhite from Minneapolis and Washington County (because of the small sample size; n=103), resulting in a baseline cohort of 15 365 participants. We then identified 2625 cases of incident AF after the baseline study visit. Because of the potential bias introduced by anticoagulant use when studying stroke risk, participants with anticoagulant use within 1 year of AF diagnosis (n=172) were excluded. We also excluded those without follow-up beyond AF date (n=224), resulting in a final cohort of 2229 participants with incident AF. Two-dimensional (2D) and 3-dimensional (3D) echocardiograms were performed during visit 5 (2011-2013) . 2D echocardiograms were performed on 6538 participants during visit 5. As previously done, exclusions were made for race (n=42), resulting in 6496 participants. Of these participants, 6008 had interpretable ECGs with PWI values. Of these, 5830 had interpretable 2D echocardiogram data. 3D echocardiograms were performed on 3035 participants during visit 5. Exclusions were made for race (n=16), poor image quality (n=1779), severe valvular heart disease or history of valve surgery (n=64), and missing body mass index or body surface area data (n=34), resulting in a final analysis cohort of 1142 participants with 3D echocardiograms.
Clinical Perspective
What Is New?
• Recent studies have highlighted limitations in the predictive value of the CHA 2 DS 2 -VASc score.
• We found that in people with atrial fibrillation, abnormal P-wave indices during sinus rhythm are associated with stroke independent of CHA 2 DS 2 -VASc variables.
• We derived the P 2 -CHA 2 DS 2 -VASc score-abnormal P-wave axis (2 points), age (1 point for 65-74, 2 points for ≥75), sex (1 point for female), heart failure (1 point), hypertension (1 point), diabetes mellitus (1 point), previous myocardial infarction/ peripheral artery disease (1 point), and prevalent stroke/transient ischemic attack (2 points)-for the prediction of atrial fibrillation-related stroke using data from 2 large community-based prospective cohort studies.
What Are the Clinical Implications?
• Use of markers reflecting left atrial remodeling, such as P-wave indices, are important for strokerisk prediction in people with atrial fibrillation. • If our findings are validated in other independent cohorts, use of the P 2 -CHA 2 DS 2 -VASc score may help improve atrial fibrillation-related stroke-risk assessment in the general population. Further details on study protocol and procedures have been previously described. 23 Approval for the study was obtained from the institutional review board on human research at each participating institution, and all participants provided informed consent.
The present analysis utilized data obtained during the baseline visit in 2000-2002 through 2014. We excluded participants with prevalent AF (n=66) or missing ECG or P-wave indices at baseline (n=49), and we identified 876 cases of incident AF. We then excluded those without follow-up beyond the date of AF diagnosis (n=117), oral anticoagulant use within 1 year of AF diagnosis (n=54), and those with invalid P-wave axis measurements (n=5), resulting in a final cohort of 700 participants with incident AF.
Measurement of P-Wave Indices
Measurement of PWIs in ARIC 17 and MESA 23 was done in a consistent manner and has been described. We evaluated P-wave axis, P-wave duration, advanced interatrial block (aIAB), and P-wave terminal force in lead V1 using a standard 12-lead ECG ( Figure 1 ). P-wave axis is a measure of the net direction of atrial depolarization. It is determined by measuring net-positive or net-negative P-wave deflections on all 6 limb leads and calculating the net direction of electric activity using the hexaxial reference system (Figure 1 ). It is a standard, computer-generated ECG index that was reported on all ECGs in ARIC and MESA. Abnormal P-wave axis (aPWA) was defined as any value outside 0° to 75°. P-wave duration is a reflection of the time required for right and left atrial depolarization. It was measured from the conclusion of the T-P segment (P-wave onset) to return to baseline (PR interval). For biphasic P-waves, P-wave duration encompassed both positive and negative deflections from baseline. Prolonged P-wave duration (PPWD) was present if the maximum P-wave duration in any lead was >120 ms on a standard 12-lead ECG. aIAB is an indicator of interatrial conduction block in Bachman's bundle such that the left atrium is activated superiorly. It was defined as PPWD+biphasic P-wave morphology in leads III and aVF with biphasic morphology or notched morphology in lead II. P-wave terminal force in lead V1 is a measure of left atrial activation. It is determined by multiplying the duration (ms) and depth (μV) of the downward deflection (terminal portion) of the P-wave in lead V1. Abnormal P-wave terminal force in lead V1 (aPTFV1) was defined as ≤−4000 μV*ms. All P-wave indices were computed from the closest sinus rhythm ECG before AF diagnosis.
Stroke Classification
Details on stroke identification and specific classification criteria for ischemic stroke in the ARIC 24 and MESA 25 cohorts have been described. In ARIC, potential cases of stroke were identified from review of hospital records and death certificates. Classification of stroke was then adjudicated by physicians with the assistance of a computerized algorithm utilizing validated criteria from the National Survey of Stroke by the National Institute of Neurological Disorders. Strokes were classified as definite or probable thrombotic stroke, definite or probable cardioembolic stroke, definite or probable subarachnoid hemorrhage, definite or probable brain hemorrhage, and possible stroke of undetermined type. The primary end point in our study was ischemic stroke, which included all thrombotic and cardioembolic strokes (definite and probable).
In MESA, potential stroke cases were identified from review of medical records and death certificates. Stroke was defined as a focal neurological deficit lasting 24 hours or until death or if the deficit lasted <24 hours and there was a clinically relevant lesion on brain imaging. Cases with focal neurological deficits secondary to brain trauma, tumor, infections, or other nonvascular cause were excluded. Cases were physician adjudicated by members of the MESA study events committee. Strokes were subclassified as subarachnoid hemorrhage, intraparenchymal hemorrhage, other hemorrhage, brain infarction, or other stroke. We included all nonhemorrhagic strokes in our analysis. Because of the relatively low number of stroke events, we elected to use a composite primary end point of stroke and transient ischemic attack (TIA) for the MESA analysis. In MESA, TIA was defined as ≥1 documented episode of focal neurological deficit lasting 30 seconds to 24 hours without brain imaging documenting stroke.
Assessment of Covariates
The covariates included in our analysis-age, sex, heart failure, 26, 27 hypertension, 28, 29 diabetes mellitus, 29, 30 myocardial infarction, 27, 31 stroke, TIA, 32 and peripheral arterial disease 27, 33 -were derived from data obtained during participant interviews, clinical examinations, and review of medical records as previously described. Prevalent (at baseline visit) and incident (during follow-up) variables were included. Precise definitions were comparable in ARIC and MESA. All covariates in ARIC and MESA were ascertained at the time of AF diagnosis or at the most recent study visit examination before AF diagnosis.
AF Ascertainment
AF cases were ascertained by review of ECGs during study visits and hospital discharge records. AF associated with cardiothoracic surgery was not considered. Further details on specific ascertainment procedures in ARIC 34 and MESA 35 have been previously described.
Anticoagulation Status
Use of anticoagulants was captured through participant interviews during each study visit in MESA and ARIC and annually in ARIC after 2006. During the time period of our analysis in both ARIC and MESA, Coumadin was the only anticoagulant captured during participant interviews.
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Echocardiography
2D and 3D echocardiography analysis protocols have been previously described. 36, 37 Briefly, 2D echocardiograms were performed using dedicated Philips iE33 Ultrasound systems with Vision 2011. 3D echocardiograms were performed using a dedicated Philips X3-1 transducer. Echocardiograms were analyzed at the Echocardiography Reading Center (Brigham and Women's Hospital) in accordance with American Society of Echocardiography recommendations.
N-Terminal Pro B-Type Natriuretic Peptide Levels
N-terminal pro B-type natriuretic peptide levels were measured from participant plasma samples obtained during ARIC visit 5 using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer (Roche Diagnostics).
Statistical Analysis
We used the ARIC sample to derive a novel risk score for AF-related ischemic stroke prediction by incorporating PWIs with the CHA 2 DS 2 -VASc score variables. We used the MESA sample to validate our risk score.
In the ARIC sample, we used Cox proportional hazards models to calculate hazard ratios (HRs) and 95% CIs of abnormal PWIs for ischemic stroke. Person-years at risk were calculated from the date of AF ascertainment until the date of ischemic stroke, death not because of stroke, loss to follow-up, or end of follow-up, whichever occurred first.
We constructed 2 models for the association of each PWI and CHA 2 DS 2 -VASc variable with incident ischemic stroke in ARIC. Model 1 was an unadjusted model. Model 2 was adjusted for remaining CHA 2 DS 2 -VASc variables: age, sex, heart failure, hypertension, diabetes mellitus, previous stroke/TIA, previous myocardial infarction, and peripheral arterial disease.
To estimate the predictive value of PWIs for stroke, we constructed 6 models for 1-year stroke risk that were used in our cohort of participants with incident AF. Model A was constructed with the CHA 2 DS 2 -VASc score variables. Models B to E were constructed by adding aPWA, PPWD, aPTFV1, and aIAB to model A, respectively. Model F was constructed by adding all 4 PWIs to model A. We evaluated model A through D, Prolonged P-wave duration (A), abnormal P-wave axis (B), abnormal P-wave terminal force in V1 (C), and advanced interatrial block (D). A, The maximal P-wave duration is seen in lead II (136 ms). The P-wave axis on B is −27°. B, The grey area on the hexaxial reference system (lead I 0°, lead II 60°, aVF 90°, aVR −150°, aVL −30°) represents normal P-wave axis (0-75°). C, The P-wave terminal force is −9632 μV*ms (amplitude −112 μV, duration 86 ms). D, The maximal P-wave duration is seen in lead III (136 ms). Biphasic P-waves can be seen in III and aVF.
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performance by calculating the C-statistic, categorical net reclassification improvement (NRI), and relative integrated discrimination improvement (IDI) using model A as the benchmark for comparison. Reclassification categories were defined as <1%, 1% to 2%, and >2% 1-year risk of stroke. We used the Hosmer-Lemeshow χ 2 statistic to evaluate model calibration and also compared observed to predicted stroke rates for score categories.
To create our risk score for 1-year stroke prediction, we screened our results for PWIs that resulted in meaningful improvement in risk reclassification and model discrimination. To assign a point value for the candidate PWI, we compared the coefficient of the PWI with the coefficient of CHA 2 DS 2 -VASc variables in the same Cox proportional hazards model for ischemic stroke. We validated the new score in MESA.
To estimate the odds of structural heart disease for abnormal PWIs, we conducted a cross-sectional analysis in participants from visit 5 who underwent 2D and 3D echocardiograms. We utilized logistic regression models to calculate odds ratios. Model A was unadjusted. Model B was additionally adjusted for age, sex, and race. Data are presented as odds ratios (95% CI) for categorical variables and difference (95% CI) for continuous variables.
Finally, we calculated the C-statistic of the CHA 2 DS 2 -VASc score for 5-year ischemic stroke in participants without AF with abnormal PWIs and participants with AF. For participants without AF, we used our baseline cohort (15 365 participants at visit 1). Baseline ECGs were used to evaluate PWIs. For participants with AF, we utilized our cohort of participants with incident AF (2229 participants with incident AF). Participants were followed until their first ischemic stroke, death, or censorship.
The proportional hazards assumption was assessed with scaled Schoenfeld residuals for both graphical and numeric tests, time interaction terms, and inspection of log-negative log survival curves. Model assumptions were not violated in any model. Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc) and STATA 13.0 (StataCorp LP). To evaluate whether differences between baseline characteristics were statistically significant, a Student t test was used for continuous variables and a χ 2 test was used for categorical variables. All P values reported were 2-sided, and statistical significance threshold was chosen as 0.05.
RESULTS
In the ARIC sample, we identified 163 ischemic strokes over a mean follow-up time of 5.4 years after AF diagnosis. There were 47 ischemic strokes within the first year after AF diagnosis. In the MESA sample, we identified 31 cases of stroke/TIA over a mean follow-up time of 3.3 years after AF diagnosis. There were ≤10 cases of stroke/TIA within the first year after AF diagnosis. Because of the Centers for Medicare and Medicaid Services sparse cell suppression policy, which stipulates that no cell (eg, admittances, discharges, patients, services) ≤10 may be displayed, we are unable to report the exact number of events in the first year after AF diagnosis. The mean (SD) time period from ECG detection of aPWA to AF diagnosis in ARIC and MESA was 8.0 (5.3) and 4.4 (3.0) years, respectively.
The baseline characteristics of participants at the time of AF diagnosis in each study sample are listed in Table 1 . In the ARIC sample, participants who developed stroke were more likely to be women and to have prevalent heart failure, hypertension, myocardial infarction, stroke/TIA, peripheral arterial disease, aPWA, PPWD, aPTFV1, and aIAB. There were no statistically significant differences in the CHADS 2 and CHA 2 DS-2 VASc scores between participants who did and did not develop stroke. In the MESA sample, participants who developed stroke were on average older, more likely to be women, and more likely to have prevalent hypertension, heart failure, stroke/TIA, and aPWA than MESA participants who did not develop stroke. Participants who developed stroke or TIA in MESA had higher CHADS 2 and CHA 2 DS 2 -VASc scores compared with those who did not. Table 2 lists the results of our Cox proportional hazards models that were used to estimate the association between abnormal PWIs and ischemic stroke in the ARIC cohort. aPWA and aIAB were associated with increased risk of ischemic stroke in the unadjusted model (model 1). These associations remained significant after adjustment for the individual CHA 2 DS 2 -VASc variables (model 2). PPWD and aPTFV1 were not associated with increased risk of ischemic stroke in either model. Table 3 lists our analysis of stroke-risk prediction model discrimination, risk reclassification, and calibration. Model A, which was constructed with the CHA 2 DS 2 -VASc variables, served as our benchmark for stroke prediction. aPWA was the only PWI that resulted in meaningful improvement in discrimination and risk reclassification. Based on our findings that aPWA was the only PWI that significantly improved the prediction of ischemic stroke, we constructed a new risk score by incorporating aPWA into the CHA 2 DS 2 -VASc score. In model B, the β estimates of aPWA and CHA 2 DS 2 -VASc score, modeled as a continuous variable, for 1-year stroke risk were 0.582 and 0.262, respectively. Thus, aPWA was assigned a value of 2 points to create the P 2 -CHA 2 DS 2 -VASc score-aPWA (2 points), age (1 point for 65-74, 2 points for ≥75), sex (1 point for female), 185 ORIGINAL RESEARCH ARTICLE heart failure (1 point), hypertension (1 point), diabetes mellitus (1 point), previous myocardial infarction/peripheral artery disease (1 point), and prevalent stroke/TIA (2 points).
In the ARIC sample, the CHA 2 DS 2 -VASc score had modest discrimination for 1-year stroke risk when assessed by C-statistic (0.60; 95% CI, 0.51-0.69). The Table 4 ). Table 5 lists our analysis of 1-year stroke-risk reclassification using the P 2 -CHA 2 DS 2 -VASc score compared with the CHA 2 DS 2 -VASc score. In ARIC participants who developed stroke within 1 year of AF diagnosis, 14% were correctly reclassified to higher risk categories, whereas 6% were incorrectly classified to lower risk categories. In those who did not develop stroke, 20.9% were correctly reclassified to lower risk categories, whereas 5.3% were incorrectly reclassified to higher risk categories. In MESA participants who de- 
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veloped stroke within 1 year of AF diagnosis, 33.3% were correctly reclassified to higher risk categories, and no participants were incorrectly reclassified to lower risk categories. In those who did not develop stroke, 8.5% were incorrectly reclassified to higher risk categories, whereas 26.3% were correctly reclassified to lower risk categories. Figure 2 depicts the observed and predicted 1-year stroke risk for P 2 -CHA 2 DS 2 -VASc score categories in ARIC and MESA. The score was well calibrated in ARIC. Given the low number of events in MESA, some variation between observed and predicted risk is to be expected. A 2% annual stroke risk, which is the threshold for anticoagulation according to the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society 2 practice guidelines, corresponded to a score of 4 to 5.
The association of PWIs with structural heart disease is displayed in Table 6 . After adjustment for age, sex, and race, all abnormal PWIs were independently associated with left atrial enlargement, greater left ventricular mass, and greater left ventricular end diastolic dimension. PPWD, aPWA, and aIAB were associated with higher N-terminal pro b-type natriuretic peptide levels. PPWD, aPTFV1, and aPWA were associated with lower left ventricular ejection fraction, aPWA and PPWD were associated with lower left atrial emptying fraction, and aPWA was associated with lower left atrial global longitudinal strain.
The predictive value of the CHA 2 DS 2 -VASc score for 5-year ischemic stroke risk is listed in Table I IDI indicates integrative discrimination improvement; and NRI, net reclassification index. *Hosmer-Lemeshow χ 2 statistic. †For categorical NRI, we used the following categories for 1-year stroke risk: <1%, 1% to <2%, and ≥2% (based on 47 cases). ‡Model A: age, sex, stroke/transient ischemic attack, heart failure, hypertension, diabetes mellitus, myocardial infarction, and peripheral artery disease. Model B: model A+abnormal P-wave axis. Model C: model A+prolonged P-wave duration. Model D: model A+abnormal P-wave terminal force in V1. Model E: model A+advanced interatrial block. Model F: model A+abnormal P-wave axis, prolonged P-wave duration, abnormal P-wave terminal force in V1, and advanced interatrial block. 
DISCUSSION
In this study, we demonstrated that aPWA and aIAB were independently associated with AF-related ischemic stroke. We found that the use of aPWA improved ischemic stroke prediction over and above the CHA 2 DS 2 -VASc score variables. We derived and validated the P 2 -CHA 2 DS 2 -VASc score-aPWA (2 points), age (1 point for 65-74, 2 points for ≥75), sex (1 point for female), heart failure (1 point), hypertension (1 point), diabetes mellitus (1 point), previous myocardial infarction/peripheral artery disease (1 point), prevalent stroke/TIA (2 points)-for the prediction of AF-related stroke using data from 2 large community-based prospective cohort studies. We found that this scoring system had superior discrimination compared with the CHA 2 DS 2 -VASc score and resulted in significant improvement in ischemic stroke-risk reclassification. It is important to note that although aIAB was independently associated with AF-related stroke, it did not improve risk prediction in our models. This finding was likely because of its low prevalence in our population. Fibrotic atrial remodeling and enlargement are critical components of the proarrhythmic and prothrombotic substrate underlying the development of AF and AF-related stroke. 10 Measurement of PWIs forms the basis for ECG-based detection of this substrate. [11] [12] [13] [14] Our analysis supports an association between abnormal PWIs and adverse cardiac remodeling, including left atrial enlargement, an independent risk factor for the development of AF and cardioembolic/ cryptogenic stroke. 38, 39 Abnormal PWIs-PPWD, 40, 41 aIAB, 16, 42, 43 aPTFV1 17, 18, 40 , and aPWA 15,44 -have been found to be independently associated with AF and stroke in the general population, even after adjustment for AF. However, the clinical utility of PWIs has not been well established.
The CHA 2 DS 2 -VASc score is recommended for AFrelated stroke prediction despite emerging evidence that has highlighted limitations in its discriminatory capacity. In a meta-analysis of 8 clinical studies, the CHA 2 DS 2 -VASc score demonstrated only modest discrimination (C-statistic, 0.675; 95% CI, 0.656-0.694) in patients with nonanticoagulated AF. 9 Furthermore, individuals with low risk scores of 0 to 1 have still been found to have a clinically significant stroke risk. A study of 73 242 patients with low-risk AF from the National Health Insurance Research Database in Taiwan reported that the annual stroke rates of patients with CHA 2 DS 2 -VASc scores of 0 and 1 were 1.09% and 1.72%, respectively. 5 Analysis of 186 750 patients IDI indicates integrated discrimination improvement; and NRI, net reclassification improvement. *For categorical NRI, we used the following categories for stroke risk: <1%, 1% to <2%, and ≥2%. †Age (1 point for >65, 2 points for >75 years), sex (1 point for female), heart failure (1 point), hypertension (1 point), diabetes mellitus (1 point), previous myocardial infarction/peripheral artery disease (1 point), and prevalent stroke/transient ischemic attack (2 points).
‡CHA 2 DS 2 VASc+abnormal P-wave axis (2 points). 
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with AF from the same database indicated that males with a score of 1 had annual stroke rates ranging from 1.96% (95% CI, 1.56-2.42) to as high as 3.5% (95% CI, 3.27-3.74%). 4 Limitations in the predictive value of the CHA 2 DS 2 -VASc score may arise from the fact that it only measures atherosclerotic risk factors and does not completely or directly reflect mechanisms of AF-related thromboembolism. Our study is the first to incorporate ECG-based markers of atrial remodeling (PWIs) into a clinically applicable risk score that outperformed the CHA 2 DS 2 -VASc score for the prediction of AF-related stroke.
A large component of the improvement in strokerisk reclassification achieved by the P 2 -CHA 2 DS 2 -VASc score was derived from correctly identifying low-risk individuals. There is disagreement between the 2012 European Society of Cardiology 3 and the 2014 American Heart Association/American College of Cardiology/ Heart Rhythm Society 2 practice guidelines on the precise definition of low risk. Specifically, the 2012 European Society of Cardiology guidelines recommend anticoagulation for CHA 2 DS 2 -VASc score of 1, whereas the American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines recommend anticoagulation for a score of 2 and equivocate at a score of 1. Use of the P 2 -CHA 2 DS 2 VASc score may address this clinical equipoise and aid in scenarios where the perceived risk-benefit ratio of anticoagulation therapy for the prevention of AF-related stroke is unclear.
Considering PWA in stroke prediction has a practical advantage: it is automatically reported on the 12-lead ECG printout. Commercially available ECG recorders do not routinely report the other PWIs (eg, PPWD, aIAB, and aPTFV1). Calculation of these indices requires ECG digitalization and specialized analytic software to allow for precise measurements, making them impractical for everyday clinical use, particularly in the primary care setting. In contrast, P-wave axis is a routine, automated index that is reported on the 12-lead ECG printout by most commercially available ECG recorders. Thus, the P 2 -CHA 2 DS 2 -VASc score is a feasible score for use in the primary care setting.
PWA is also reproducible. Data on the short-term reliability and stability of P-wave indices are available from a subset of 63 ARIC participants. In this study, two 12-lead ECGs were obtained from participants during 2 study visits spaced 2 weeks apart. The absolute within-and between-visit difference of P-wave axis was 5.1±5.8 and 6.6±7.2 degrees, respectively. The reported intraclass correlation coefficient was 0.78. Pwave duration and P-wave terminal force were not as reliable with reported intraclass correlation coefficients of 0.58 and 0.46, respectively. 45 It is notable that we found that stroke prediction by the CHA 2 DS 2 -VASc score in people without AF but with abnormal PWI was comparable to people with AF. The CHA 2 DS 2 -VASc score has been shown to have predictive value in the absence of detected AF. 46 It is unclear whether individuals without AF will benefit from anticoagulation guided by the CHA 2 DS 2 -VASc score given the relatively lower proportion of cardioembolism compared with people with AF. However, people without AF who have underlying prothrombotic atrial remodeling may benefit from anticoagulation because stroke in this population may be cardioembolic. 15 Thus, PWIs may have a role in stroke-risk prediction and guiding anticoagulation therapy in people without AF in addition to enhancing stroke-risk prediction in people with AF. If our findings are validated in other studies, further research should be conducted to determine whether anticoagulation can reduce stroke risk in people without AF but with abnormal PWIs and other markers of atrial remodeling.
The principal strengths of our study include the use of 2 large community-based, racially diverse, prospective cohorts with long follow-up duration, extensive measurement of covariates, and rigorous physician adjudication of stroke. Some limitations should be noted. First, AF was identified primarily from hospital ORIGINAL RESEARCH ARTICLE discharge records. Thus, we were unable to account for subclinical AF or AF managed exclusively in ambulatory clinics. However, AF incidence in the ARIC study is consistent with other population-based studies, and utilizing hospital discharge records for the purposes of AF detection has been previously validated. 34, [47] [48] [49] Second, because of the low number of stroke events in the MESA study, we used a composite end point of stroke/TIA for the purposes of score validation. Third, anticoagulant use was not captured annually in MESA or ARIC (until 2006) . Therefore, we likely were unable to exclude all participants on anticoagulants within 1 year of AF diagnosis. However, the use of anticoagulants for AF-related stroke prevention in the United States did not become widespread until after 2006, when risk stratification using the CHADS 2 score was recommended by practice guidelines. 50 Thus, we do not suspect that this will have significantly biased our results. Fourth, anticoagulants other than Coumadin were not captured in ARIC. However, novel oral anticoagulants were not introduced in US markets until 2010, which is toward the end of our analysis period. Thus, aside from enoxaparin, Coumadin was likely the primary ambulatory anticoagulant used in the United States during our analysis period. Fifth, our analysis was based on PWIs obtained before AF diagnosis.
Thus, the clinical utility of the P 2 -CHA 2 DS 2 -VASc score is limited in patients with persistent or permanent AF who have no available sinus ECGs and unclear in patients with AF whose only available sinus rhythm ECGs were obtained after AF diagnosis. Finally, as inherent in all observational studies, although we adjusted for potential confounders in our analyses, we could not exclude residual confounding by imperfectly measured and unmeasured factors.
Conclusion
In summary, aPWA was associated with an increased risk of AF-related ischemic stroke. When included with CHA 2 DS 2 -VASc score variables to create the P 2 -CHA 2 DS 2 -VASc score, aPWA helped to improve the prediction of AF-related ischemic stroke in 2 large prospective community-based cohorts. Further research is needed to clarify the biological correlates of aPWA as well as its accuracy and precision in detecting a prothrombotic atrial substrate.
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The online-only Data Supplement is available with this article at https://www. ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.035411. aIAB indicates advanced interatrial block; aPTFV1, abnormal P-wave terminal force in V1; aPWA, abnormal P-wave axis; LAEF, left atrial emptying fraction; LAGLS, left atrial global longitudinal strain; NT-pro BNP, N-terminal pro b-type natriuretic peptide; and PPWD, prolonged P-wave duration.
*Data displayed as odds ratio (95% CI) unless otherwise stated. Difference is the difference in number of units (pg/mL for NT-pro BNP and % for LAGLS and LAEF) between participants with an abnormal PWI and participants with a normal PWI (eg, compared with participants with normal PWA, those with abnormal PWA have higher NT-pro BNP and lower LAGLS and LVEF). †Logistic regression models. Model A is unadjusted. Model B is adjusted for age, sex, and race. ‡P<0.05. §P<0.01.
